吉非替尼治疗晚期非小细胞肺癌疗效分析  

The efficacy of gefitinib in treating non-small cell lung cancer

作　　者：张进川[1] 李洪霞[1] 张东[1] 安莉[1] 

机构地区：[1]解放军总医院南楼呼吸科,北京100853

出　　处：《中国临床保健杂志》2007年第6期563-565,共3页Chinese Journal of Clinical Healthcare

摘　　要：目的观察吉非替尼对晚期非小细胞肺癌患者的疗效。方法对吉非替尼治疗的非小细胞肺癌22例进行分析。结果22例中可评估的14例中(5例疾病稳定,2例完全缓解,1例部分缓解)有效率21.4%,临床获益率8/14(57.2%)。结论吉非替尼对晚期非小细胞肺癌疗效较好,其副反应相对小,耐受性好。Objective To study the efficacy of Gefitinib （Iressa） in treating eld.edy patients with advanced non-small cell lung cancer. Methods 22 elderly patients with advanced non-small cell lung cancer treated by Gfitinib from Apr 2004 to Dem 2006 with Gfitinib were analyzed. Results Among 14 patients appreciable from all 22 patients, complete response（CR） in 2 cases, partial response （PR） in 1 case, stable disease （SD） in 5 cases, so the clinical benefit response（ 2 ＋ 1 ＋ 5 ） rate was 57.2% and the tumor response（ 2 ＋ 1 ） rate was 21.4%. Conclusion Gefitinib is an effective orally drug in the treatment of patients with non-small cell lung cancer. The of toxicity with Gefitinib is lower and can be well acceptable.

关 键 词：癌 非小细胞肺 肿瘤治疗方案 

分 类 号：R734.2[医药卫生—肿瘤]